Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 26;12(12):2366-2369.
doi: 10.21037/tlcr-23-743. Epub 2023 Dec 15.

Immunotherapy: remember the host

Paul R Walker  1
Affiliations
Editorial

Immunotherapy: remember the host

Paul R Walker. Transl Lung Cancer Res. .
No abstract available

Keywords: Immunotherapy; biomarkers; host.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-743/coif). P.R.W. is a current employee of Circulogene. The author has no other conflicts of interest to declare.

Comment on

References

    1. Sung M, Jang WS, Kim HR, et al. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Transl Lung Cancer Res 2023;12:1506-16. 10.21037/tlcr-23-7 - DOI - PMC - PubMed
    1. de Castro G, Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2023;41:1986-91. 10.1200/JCO.21.02885 - DOI - PMC - PubMed
    1. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021;32:881-95. 10.1016/j.annonc.2021.04.008 - DOI - PubMed
    1. Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response - sharpening the focus. Nat Rev Clin Oncol 2022;19:495-6. 10.1038/s41571-022-00634-0 - DOI - PubMed
    1. Liu N, Mao J, Tao P, et al. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. 10.1097/MD.0000000000028617 - DOI - PMC - PubMed